OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Contents page 2	233
Contents page	215
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	190
Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors	190
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	165
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	150
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	135
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants	126
The recent progress of deep-learning-based in silico prediction of drug combination	124
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	120
CIPDB: A biological structure databank for studying cation and π interactions	113
Recent development in the design of small ‘drug-like’ and nanoscale glycomimetics against Escherichia coli infections	112
General aspects of powder rheology applied to pharmaceutical formulations	108
Tubulin targeting agents and their implications in non-cancer disease management	108
The potential value of 5-androstenediol in countering acute radiation syndrome	107
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	99
Mitochondrial dysfunction: A potential target for Alzheimer’s disease intervention and treatment	96
Models and approaches to comprehend and address glial inflammation following spinal cord injury	93
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	90
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	87
Computational modeling approaches and regulatory pathways for drug combinations	86
Gastroretentive drug delivery systems: A holy grail in oral delivery	84
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	83
Antibody–drug conjugates: What drives their progress?	80
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	79

Repurposing of parenterally administered active substances used to treat pain both systemically and locally	77
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	77
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	77
Specificity of pharmacokinetic modeling of nanomedicines	76
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	76
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	76
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	74
Contents page 2	72
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	71
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	71
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics	71
Pathogenic TDP-43 in amyotrophic lateral sclerosis	70
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates	69
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	68
Molecular approaches for the treatment and prevention of Friedreich's ataxia	67
Towards Pharma 4.0 in clinical trials: A future-orientated perspective	67
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	64
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	63
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	62
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	62
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	59
Steps toward nebulization in-use studies to understand the stability of new biological entities	58
MRI assessment of cerebral perfusion in clinical trials	58
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	58
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	55
Caught between a ROCK and a hard place: current challenges in structure-based drug design	55
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance	54
Targeted protein degradation: current molecular targets, localization, and strategies	54
Recent advances towards overcoming the blood–brain barrier	54
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	54
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio	54
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	54
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	54